Heart failure & cardiomyopathies
Economic Burden of Heart Failure in Europe: A Systematic Review of Costs and Cost-Effectiveness
Authors' conclusion
F imposes a substantial economic burden in Europe, largely driven by hospitalizations.
Study context
- Population
- Heart failure (HF) across European healthcare systems; studies published January 2000–January 202449 studies
- Outcome
- Economic impact of HF diagnosis, treatment and management
Pooled result
As reported in the abstract
Annual HF-related costs per patient, range across countries
€613 to €22,647
Hospitalizations: primary cost driver, share of total HF costs
15% to 92%
Further pooled results
Cost-effectiveness of HF therapies
- ICERs of certain HF therapies, range
- €1490 to €9406 per QALY gained
Cost-reduction strategies
- Multidisciplinary care, telemonitoring and pharmacologic interventions; several disease management programmes reduced hospital admissions and ED visits
Original publication
Economic Burden of Heart Failure in Europe: A Systematic Review of Costs and Cost-Effectiveness. ESC Heart Fail. Published 26 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →